|
一、 中文文獻 (一) 書籍 1. 中華民國糖尿病學會編。《2010糖尿病臨床照護指引》。台北市:中華民國糖尿病學會,2010。 2. 財團法人生物技術開發中心。《生物技術產業年鑑2008》。台北市:財團法人生物技術開發中心,2008。 3. 曾陳明汝。《兩岸暨歐美專利法》。二版。台北:新學林,2004。 4. 黃銘傑。《競爭法與智慧財產法之交會:相生與相剋之間》。台北:元照,2006。 5. 詹炳耀。《專利鑑價》。二版。台北市:經濟部智慧財產局,2009。 (二) 期刊論文 1. 中央健康保險局。〈全民健康保險雙月刊〉。《中央健康保險局》。第83期,1996。 2. 胡釗維、何蕾。〈新藥價衝擊 病人恐無藥可醫?〉。《商業週刊》。第1142期,2009。 3. 陳堂麒、劉惠娟。〈早期偵測興起 將帶動生技製藥產業導向個人化醫療〉。《生技與醫療器材報導MD News》。第107期,2008。 4. 程馨、謝啟瑞。〈全民健保藥品政策與藥品費用的經濟分析〉。《經社法制論叢》。第35期。頁1-42,2005。 5. 張慈映。〈2012年全球醫材產業營收將突破3200億美元,生技與醫療器材報導〉。《MD News》。第100期,2007。 6. 黃銘傑。〈專利集管(Patent Pool)與公平交易法〉。《月旦法學》。第87 期,2002。 7. 黃肇明。〈揭開健保「藥價黑洞」神秘的面紗〉。《全民健康保險雙月刊》。第83期,2010。 (三) 學位論文 1. 林宛誼。《專利聯盟協議衍生之技術標準研析--以飛利浦CD-R授權案為中心》。私立東吳大學法律學研究所在職專班科技法律組碩士論文,2007。 2. 蔡宜芯。《專利集中授權(Patent Pools)之法律規範--以競爭法為中心》。國立臺灣大學法律學研究所碩士論文,2003。 3. 劉懿真。《生技製藥產業運用專利聯盟之研究》。國立中央大學產業經濟研究所法律組碩士論文,2003。 (四) 網路資源 1. 中央健康保險局。《全民健康保險藥價基準》。載於中央健康保險局網站,2009。 http://www.nhi.gov.tw/webdata/AttachFiles/Attach_4153_2_980922公布藥價基準修正條文-1(署授保字第09800000810號).pdf 2. 中央健康保險局。《全民健康保險藥事小組設置要點》。載於中央健保險局網站,2010。 http://www.nhi.gov.tw/webdata/AttachFiles/Attach_13656_2_藥事小組設置要點9901修訂.pdf 3. 中央健康保險局。《全民健康保險藥價基準》。載於中央健康保險局網站,1999。http://www.nhi.gov.tw/webdata/AttachFiles/Attach_2853_1_chi05-1a.doc 4. 中央健康保險局。《藥費控制--藥價調整》。載於中央健康保險局網站,2010。 http://www.nhi.gov.tw/webdata/webdata.asp?menu=6&menu_id=168&webdata_id=1674&WD_ID= 5. 王慰祖。《專利期優勢漸失新藥當救援投手》。載於中華民國區域醫院協會網站,2007。 http://www.rha.org.tw/news.php?mid=725 6. 生物技術開發中心。《臺灣生技產業於全球之地位及發展方向》。生物技術開發中心,2008。http://www.itis.org.tw/pubinfo.screen?industry=2&ctgy= 7. 行政院衛生署中央健康保險局。《行政院衛生署中央健康保險局令:修正「全民健康保險新藥收載及核價作業標準」,並修正名稱為「全民健康保險新藥收載及核價作業須知」,自99年3月9日生效》。載於行政院公報資訊網,2010。 http://gazette.nat.gov.tw/EG_FileManager/eguploadpub/eg016043/ch08/type2/gov70/num15/OEg.pdf 8. 美國商會。《美國商會2009年白皮書》,2009。 http://www.amcham.com.tw/index2.php?option=com_docman&task=doc_view&gid=345&Itemid=377 9. 國科會。《基因體醫學國家型科技計畫》。載於基因體醫學國家型科技計畫網站,2010。http://nrpgm.sinica.edu.tw/content.php?cat=agtc 10. 曾千芳。《健保藥價基準修訂原則說明》。載於中景康藥學基金會網站,2006。http://www.ckf.org.tw/pdf/1100.pdf 11. 黃文鴻。《全民健康保險藥品費用支出變動因素之分析》。載於行政院衛生署中央健康保險局96年度委託研究成果:DOH96-NH-1007,2007。http://210.69.214.131/96/96plan008.htm 12. 莊雅善。《化學:綠螢光蛋白研究先驅 日華美裔科學家同摘諾貝爾化學獎》。載於Sciscape網站,2008。http://www.sciscape.org/news_detail.php?news_id=2395 13. 廖美智。《2008年全球及我國生技產業的脈動》。載於生物技術開發中心網頁,2008。 http://www.itis.org.tw/pubinfo.screen?industry=2&ctgy= 14. 衛生署。《95年度衛生統計動向》。載於衛生署網站,2006。 http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=9884&class_no=440&level_no=2 15. 衛生署。《95年度國民醫療保健支出:提要分析》。載於衛生署網站,2006。http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=9874&class_no=440&level_ no=2 16. 蔡蘊明。《水母的綠色螢光如何造成生命科學的革命性發展》。載於臺灣大學網站,2008。http://www.ch.ntu.edu.tw/nobel/nobel97.htm 二、 外文文獻 (一) Books 1. Adam B. J, Josh L., Scott S. Innovation Policy and the Economy. Cambridge:MIT Press, 2001. 2. Masako Wakui, Valuing Intellectual Property in Japan, Britain and the United States. New York, RoutIedgeCurzon, 2004. 3. Phillip E. A., Herbert H., Roger B. Antitrust Law: An Analysis of Antitrust Principles and Their Application. Aspen Publishers, 2000. 4. Suzanne scotchmer Innovation and Incentives, Cambridge, MIT Press. (2004) 5. William M. Landes, Richard A. Posner. The Economic Structure of Intellectual Property Law. Cambridge, Belknap Press of Harvard University Press, 2003. (二) Periodical Materials 1. Anna S. F. L and Brian J. Mc. Aasld Practice Guidelines: Chronic Hepatitis B: Update 2009, Hepatology, Vol. 50, no. 3, September, pp. 1-30, 2009. 2. Carl Shapiro. Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard Setting, NBER Conference on Innovation Policy and the Economy, May, pp. 1-32, 2010. 3. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals, Clin Drug Investig, Vol. 28, No. 11, pp. 713-734, 2008. 4. David S. Taylor. The Sinking of the United States Electronics Industry Within Japanese Patent Pools, The George Washington Journal of International Law and Economics, Vol. 26, Iss. 1, January, pp. 26, 1992. 5. Ebersole TJ, Guthrie MC, Goldstein, J. A. Patent pools and standard setting in diagnostic genetics, Nature Biotechnology, Vol. 23, pp. 937-938, 2005. 6. George Tsai. Canada’s Access to Medicines Regime:Lessons for Compulsory Licensing Schemesunder the WTO Doha Declaration, Virginia Journal of International Law, Vol. 49 , Iss. 4 , pp.1063-1097, 2009. 7. Gold Er. SARS genome patent: symptom or disease?, Lancet, Vol. 361, pp. 2002-2003, 2003. 8. Grassler F, Capria MA. Patent pooling: Uncorking a technology transfer bottleneck and creating value in the biomedical research field, Journal of Commercial Biotechnology, Vol. 9, No. 2, January, pp. 111-118, 2003. 9. Hardin, G. The Tragedy of the Commons, Science, Vol. 162, No. 3859, December, pp. 1243-1248, 1968. 10. Jakkrit Kuanpoth, Intellectual Property Rights and Pharmaceuticals: A Thai Perspective on Prices and Technological Capability, Thammas at Economic Journal, Vol. 25, No. 4, December, pp. 1-47, 2007. 11. Jerome H. Reichman. Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options, The Journal of Law, Medicine & Ethics, Vol. 37, Iss. 2, pp. 247-263, 2009. 12. JHM Simon, E Claassen, Ce Correa, Adme. Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling , Bulletin of World Health Organization, Vol. 83, pp. 707-710, 2005. 13. John H. Barton. Antitrust Treatment of Oligopolies with Mutually Blocking Patent Portfolios, Antitrust Law Journal, Vol. 69, pp. 851-882, 2002. 14. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome, Nature, Vol. 409, Feb., pp. 860-921, 2001. 15. Michael A. Heller, M. A, and Eisenberg, R.S. Can Patents Deter Innovation? The Anticommons in Biomedical Research, Science, Vol. 280. No. 5364, May, pp. 698-701, 1998. 16. Natasha Gilbert. Drug patent plan gets mixed reviews, Nature, Vol. 457, Feb., pp. 1064-1065, 2009. 17. Neutel JM. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients, Curr Med Res Opin, Vol. 24, No. 8, Aug., pp. 2389-2401, 2008. 18. Newberg, Joshua A. Antitrust, Patent Pools, and the Management of Uncertainty, ATLANTIC L. J. , Vol. 3, pp. 1-30, 2000. 19. Peter Maybardule & Sarah Rimmingto. Compulsory Licenses: A Tool to Improve Global Access to the HPV Vaccine?, Am J Law Med, Vol. 35, No.2-3, pp. 323-350, 2009. 20. Potrykus, I. Golden rice and beyond, Plant Physiol, Vol. 125, pp.1157-1161, 2001. 21. Roger B. Andewelt. Analysis of Patent Pools Under the Antitrust Laws, Antitrust L.J., Vol. 53, pp. 611-619, 1984. 22. Steven C. Carlson. Patent Pools and the Antitrust Dilemma, Yale Journal on Regulation, Vol. 16, Mar., pp. 359-399, 1999. 23. Subhasis Saha. Patent Law and TRIPS: Compulsory Licensing of Patents and Pharmaceuticals, Journal of the Patent and Trademark Office Society, Vol. 91, May, pp.364-374, 2009. 24. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome, Science, Vol. 291, Feb., pp. 1304-1351, 2001. 25. Verbeure B., Van Zimmeren E., Matthijs G., Van Overwalle G. Patent pools and diagnostic testing, Trends in Biotechnology, Vol. 24, No. 3, March, pp.115-120, 2006. 26. Watson J.D., Crick F.H.C. A Structure for Deoxyribose Nucleic Acid, Nature, Vol. 171, Apr., pp. 737-738, 1953. (三) Case 1. Pope Manufacturing Company v. Gormully, 144 U.S. 224, 234 (1892). 2. United States v. Line Material Co., 333 U.S. 287, 313 n. 24 (1948). 3. United States v. Singer Manufacturing Company, 374 US. 174, 199 (1963) (四) Website 1. Biological Science. Martin Chalfie wins the Nobel Prize in Chemistry for lighting up Cells, Columbis University, 2008. http://www.columbia.edu/cu/biology/news-events-data/news/marty-08/index.html 2. Clark, J. Patent pools: a solution to the problem of access in biotechnology patents? , United States Patent and Trademark Office, 2000. http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool. pdf 3. Clarkson, G. Patent Informatics for Patent Thicket Detection: A Network Analytic Approach for Measuring the Density of Patent Space, Academy of Management, 2005. http://w4.stern.nyu.edu/emplibrary/ACFNpuvR7.pdf 4. Colangelo, G. Avoiding the Tragedy of the Anticommons: Collective Rights Organizations, Patent Pools and the Role of Antitrust, LUISS Law and Economics Lab Working Paper No. IP-01-2004, 2004. http://ssrn.com/abstract=523122 or doi:10.2139/ssrn.523122 5. Consumer Project on Technology. Talking points on Cipro patent dispute, CPTech, 2001. http://www.cptech.org/ip/health/cl/cipro/talkingpoints.html 6. Consumer Project on Technology. HHS, Bayer Agree to Cipro Purchase, CPTech, 2001. http://www.cptech.org/ip/health/cl/cipro/dhhs10242001.html 7. Donald Zuhn. Alnylam to Donate RNAi Patents to Patent Pool, Patent Docs, 2009. http://www.patentdocs.org/2009/08/alnylam-to-donate-rnai-patents.html 8. Donald Zuhn. EU Trade Commissioner Sends Warning Letter to Thailand, Patent Docs, 2007. http://www.patentdocs.org/2007/08/eu-trade-commis.html 9. Fellig, Menachem M. Patent pools and Competition Law : an Examination of the Enforcement Strategies of Competition Authorities, Université de Montréal, 2008. https://papyrus.bib.umontreal.ca/jspui/handle/1866/2546?locale=en 10. Federal Trade Commission. Summit and VISX Settle FTC Charges of Violating Antitrust Laws, Federal Trade Commission, 1998. http://www.ftc.gov/opa/1998/08/sumvisx.shtm 11. GFP technology aids drug discovery and development. GE Healthcare Announces Agreements with Bristol-Myers Squibb and Regeneron Pharmaceuticals for Green Fluorescent Protein, GE healthcare website, 2008. http://www.gehealthcare.com/company/pressroom/releases/pr_release_10165.html 12. Golden Rice Humanitarian Board , http://www.goldenrice.org/ 13. Goldenrice. A Public-Private Partnership and Humanitarian Licences, Goldenrice, 2010. http://www.goldenrice.org/Content2-How/how9_IP.html 14. Goldenrice. The Golden Rice Network, Goldenrice, 2010. http://www.goldenrice.org/Content1-Who/who3_collab.html 15. Goldenrice. Humanitarian use, Goldenrice, 2010. http://www.goldenrice.org/Content1-Who/who4_IP.html 16. Goldenrice. Expertise and Strategic Guidance, Goldenrice, 2010. http://www.goldenrice.org/Content1-Who/who1_humbo.html 17. Goldenrice. The road to the farm is bumpy, Goldenrice, 2010. http://www.goldenrice.org/Content1-Who/who2_history.html 18. HHS Press Office. Hhs, Bayer Agree to Cipro Purchase, Comsumer Project on Technology, 2001. http://www.cptech.org/ip/health/cl/cipro/dhhs10242001.html 19. James P. Love. Recent Examples of the Use of Compulsory Licensing of Patents, Knowledge Ecology, KEI Research Note 2007:2, 2007. http://www.keionline.org/misc-docs/recent_cls.pdf 20. Jason Derry. No New Abbott Medicines for Thailand, Patent Docs, 2007. http://patentdocs.typepad.com/patent_docs/2007/03/no_new_abbott_m.html 21. Kryder D, Kowalski SP, Krattiger AF. The Intellectual and Technical Property Components of pro-Vitamin A Rice (GoldenRice™): A Preliminary Freedom-To-Operate Review, ISAAA, 2000. https://www.isaaa.org/Resources/publications/briefs/20/download/isaaa-brief-20-2000.pdf 22. Knowledge Ecology International. The Essential Medical Inventions Licensing Agency, 2007. http://www.keionline.org/misc-docs/emila.pdf 23. Krisana Kraisintu. Local Resources for Global Remedies, Asia Society, 2008. http://www.asiasociety.org/policy-politics/global-health/hiv-aids/local-resources-global-remedies 24. Kevin E. Noonan. Thailand Continues Its Compulsory Licensing Practices, Patent Docs, 2008. http://www.patentdocs.org/2008/03/thailand-contin.html 25. KEI Research. IGWG Briefing Paper on Patent Pools:Collective Management of Intellectual Property -- The use of Patent Pools to expand access to essential medical technologies, KEI Research Note 2007:3 (1), 2007. http://www.keionline.org/content/view/65/1 26. Layne-Farrar, A., Lerner, J. To Join or Not to Join: Examining Patnet Pool Participation and Rent Sharing Rules, 2008. http://ssrn.com/abstract=945189 27. OECD. Guidelines for the Licensing of Genetic Inventions, OECD, 2006. http://www.oecd.org/dataoecd/39/38/36198812.pdf 28. Serafino, D. Survey of Patent Pools Demonstrates Variety of Purposes and Management Structures, KEI Research Note 2007:6, 2007. http://www.keionline.org/index.php?option=com_content&task=view&id=69 29. The Ministry of Public Health And The National Health Security Office. The 10 burning questions regarding the Government Use of Patents on the four anti-cancer drugs in Thailand, Ministry of Public Health, 2008. http://www.moph.go.th/hot/White%20paper%20CL%20II%20FEB%2008-ENG.pdf 30. UNITAID. UNITAID Annual Report2008, UNITAID, 2008. http://www.unitaid.eu/images/news/annual_report_2008_en.pdf 31. UNITAID. The way it works, UNITAID, 2007. http://www.unitaid.eu/en/The-way-it-works.html 32. UNITAID, UNITAID: Mission, UNITAID, 2007. http://www.unitaid.eu/en/UNITAID-Mission.html 33. Warren Kaplan, Centre for International Health & Development, Boston University New ICTSD Series on New Opportunities through Innovation:Fostering R&D and Promoting Access to Medicines, October 2007. http://www.iprsonline.org/ictsd/Dialogues/2007-10-22/Kaplan-%20Patent%20Pools.pptm 34. Warren A. Kaplan. New ICTSD Series on New Opportunities through Innovation:Fostering R&D and Promoting Access to Medicines, 2007. http://www.iprsonline.org/ictsd/Dialogues/2007-10-22/Kaplan-%20Patent%20Pools.pptm 35. World Health Organization. CIPIH report: main recommendations, Bulletin of the World Health Organization, 2006. http://www.who.int/bulletin/volumes/84/5/CIPIH_report/en/index.html 36. World Health Organization. Public health, innovation and intellectual property rights: report of the Commission on Intellectual Property Rights, Innovation and Public Health, World Health Organization, 2006. http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf 37. World Health Organization. Do patents work for public health?, World Health Organization, 2006. http://www.who.int/bulletin/volumes/84/5/who_news.pdf
|